



**SUSTAINABILITY
REPORT
2021**



**ENGAGING IN
SUSTAINABLE PRACTICES**



CONTENTS

About this Report	2
Sustainability Board Statement	3
About TalkMed	4
Sustainability at TalkMed	7
Stakeholder Engagement	8
Materiality Assessment	9
Governance	
• Anti-Corruption	10
Product Responsibility	
• Customer Health and Safety	11
People	
• Employment	12
• Training and Education	14
Community	15
GRI Content Index	16

ABOUT THIS REPORT

GRI 102-1 | 102-46 | 102-50 | 102-52 | 102-53 | 102-54

TalkMed Group Limited (“**TalkMed**” or the “**Company**”) is pleased to present our fifth annual Sustainability Report. This report reaffirms our commitment to sustainability and discloses our environmental, social and governance performance for the financial year ended 31 December 2021 (“**FY21**”). The scope of the report covers our operations in Singapore.

The FY21 Sustainability Report has been prepared in accordance with the Global Reporting Initiative (GRI) Standards: Core option. The GRI standards were chosen as they are the first global standards for sustainability reporting. The GRI Content Index on pages 16 to 19 contains the list of GRI references used in this report. This report is also formed with reference to the primary components set out in Singapore Exchange Limited listing Rule 711B on a ‘Comply or Explain’ basis.

We value the feedback of our stakeholders and welcome questions you may have on any aspect of our sustainability performance. Please write to:

enquiries@talkmed.com.sg



SUSTAINABILITY BOARD STATEMENT

GRI 102-14



TalkMed Group is pleased to present our fifth Sustainability Report for the financial year ended 31 December 2021. Our report documents our sustainability performance, progress and the initiatives we have adopted to meet our stakeholders' expectations.

ENVIRONMENT

We are aware of our responsibility to conduct our business in an environmentally responsible manner. We strive to minimise the harmful environmental impacts of our day-to-day practices and integrate sustainable practices across all business operations. Through sustainability reporting, we would be able to track the progress of our initiatives and create greater environmental consciousness among our community.

At TalkMed, we understand the dangerous effects of improper handling and disposal of medical waste on the environment as well as the society. We are therefore committed to adopt the best practices and ensure compliance with all relevant regulations. This helps minimise the risk of disease transmission, air and water contamination, as well as soil pollution. We hire licensed and experienced firms to collect, transport and dispose of any biohazardous and cytotoxic waste.

SOCIAL

As a medical service provider, we understand the importance of attracting and retaining talented employees to provide exceptional service to our customers. We are committed to enforcing fair labour practices, providing equal opportunities and providing a safe working environment for all our employees.

At TalkMed, we have created a culture that fosters innovation and encourage our medical staff to stay up to date with the latest development in their field. We provide them with diverse training opportunities and support their professional as well as personal development. This helps them to be aware of the latest medical advancement, treatment methods and equipment available in the market and allows them to make well-informed decisions for our customers.

Our ultimate goal is to provide quality and safe patient care that exceeds industry standards and responds to the needs of our customers. We believe that maintaining a safe environment is a crucial aspect of competent healthcare. To protect the safety of both patients and our healthcare professionals, we ensure strict adherence to all applicable rules and regulations.

TalkMed values its employees, customers and the community it serves. Our doctors play their part by providing health education to the people. They share their knowledge and contribute to raising disease awareness in Singapore and neighbouring countries via newspapers, magazines, medical journals and medical educational sessions.

COMMUNITY

We strive to have a positive impact on our community and have collaborated with the Singapore Cancer Society to create a difference. As part of our local initiatives, we sponsored and participated in the "Relay for Life" event in Singapore.

GOVERNANCE

We understand our role as a member of the medical fraternity and uphold the highest standards of corporate governance across all our business functions. To demonstrate our commitment to business ethics, we have included anti-corruption as one of the material topics in our report to disclose our practices, policies and performance. We strictly adhere to the compliance requirements of a public listed company and are committed to providing transparent and relevant information to all our stakeholders on a timely basis.


TalkMed believes our responsibility as a healthcare group goes beyond our business operations. We are committed to look for ways to enhance our services and use our resources responsibly. We strive for medical excellence and aim to provide the safest services to our valuable customers. We want to thank our stakeholders for their continuous trust and support in our sustainability journey.

ABOUT TALKMED

GRI 102-2 | 102-3 | 102-4 | 102-5 | 102-6 | 102-7 | 102-8

TalkMed and its group of companies (collectively, the “**Group**”) is a premier provider of medical oncology services, stem cell transplant services and palliative healthcare services. We are headquartered in Singapore and our operations extend to serve the markets in Vietnam and Hong Kong as well as the People’s Republic of China (“**PRC**”).

TalkMed was incorporated on 10 September 2013 and listed on the Catalist Board of Singapore Exchange Securities Trading Limited on 30 January 2014. TalkMed has transferred its listing from the Catalist to the Mainboard on 28 April 2022. TalkMed’s group structure as of May 2022 is as follows:



(a) The Group exercises control over and derives economic benefits from the remaining 10% interest in the entity through contractual arrangements.

(b) Operates TalkMed Shanshui Medical Centre.

SINGAPORE

Singapore Cancer Centre Pte. Ltd. (“**SCC**”) provides tertiary healthcare services to the oncology patients in the private sector in Singapore, through Parkway Cancer Centre (“**PCC**”). Our highly-trained doctors attend to patients, examine and administer medical treatments, perform minor outpatient surgical procedures, prescribe medicines and conduct laboratory tests or diagnostic procedures. In addition to the above clinical functions, we review the results of these investigations and provide follow-up patient care.

TalkMed is recognised as one of the leading medical tourism facilities in Singapore. This has been made possible by the excellent medical services provided by our team of sixteen doctors at nine clinics in facilities operated by Parkway Hospitals Singapore Pte. Ltd.. These include Gleneagles Hospital Singapore, Mount Elizabeth Hospital Singapore, Mount Elizabeth Medical Centre and Mount Elizabeth Novena Specialist Centre. For the past few years, SCC has established itself as one of the market leaders in medical tourism in Singapore with foreign patients accounting for approximately half of its patient- load.

CellVec Pte. Ltd. was incorporated on 8 August 2018 and is primarily engaged in the provision of cellular and gene therapy related products and services, with a focus on the development of novel platform viral vector technologies that strive to advance genetic modification of cellular therapy.

In November 2019, TalkMed Greater China Pte. Ltd. was incorporated pursuant to a restructuring exercise to consolidate and streamline the Group’s projects in the PRC. It is used by the Group as a vehicle to hold its current projects in Beijing and Chongqing through TalkMed China Pte. Ltd. (“**TMC**”) and TalkMed Chongqing Pte. Ltd. (“**TMCQ**”) respectively as well as to explore future healthcare-related projects collaborations in the PRC.

ABOUT TALKMED

GRI 102-2 | 102-3 | 102-4 | 102-5 | 102-6 | 102-7 | 102-8

BEIJING

The Group has a 100% deemed interest in Beijing Yachuang Siwei Investment Management Co., Ltd. ("**Yachuang**"), after TMC, a wholly-owned subsidiary of the Group acquired 70% and 20% of the total issued and paid-up share capital of Yachuang in January 2020 and August 2021 respectively. The remaining 10% stake is held through contractual arrangements.

Yachuang is principally engaged in the business of investment management, hospital management, and healthcare management and consultancy (excluding diagnosis and treatment). Yachuang's wholly-owned subsidiary, Beijing Deyi Shanshui Clinic Co., Ltd., operates a private medical centre in Beijing, PRC, known as TalkMed Shanshui Medical Centre ("**TSMC**") offering premier and quality oncology services as well as ancillary services to support oncology patients in the PRC. TSMC has obtained the practice licence of medical institution in May 2021 and commenced operations in August 2021.

TalkMed Hospital Management (Beijing) Co., Ltd. is 100% owned by TMC, and its principal activity is to provide hospital management and advisory services in the PRC.

CHONGQING

TMCQ, a wholly-owned subsidiary of the Group, was incorporated with the aim to provide healthcare management services in Chongqing, PRC. TMCQ has jointly established a sino-foreign joint venture enterprise, Sino-Singapore Hospital Management (Chongqing) Co., Ltd. ("**SSHM**") in Chongqing, PRC, with Chongqing Yongchuan District People's Hospital ("**YCDPH**"). TMCQ and YCDPH hold 60% and 40% of the equity interests in SSHM respectively. Through SSHM, the Group operates a category 2A oncology hospital in the Yongchuan District, Western Chongqing, known as Sino-Singapore Cancer Centre ("**SSCC**"). SSCC obtained the practice licence of medical institution in April 2021 and commenced operations in June 2021.

In August 2021, TMCQ has also jointly established a joint venture company, Chongqing Medtech Health Management Co., Ltd. ("**CMHM**") in Chongqing, PRC, with joint venture partners, Chongqing Yijisheng Pharma Technology Co., Ltd. ("**CYPT**") and Chongqing Tuozhen Information Technology Co., Ltd. ("**CTIT**"). CMHM's principal activity is to assist partner hospitals in the PRC to establish internet hospitals and operate their internet pharmacies. TMCQ, CYPT and CTIT hold 30%, 51% and 19% of the equity interest in CMHM respectively.



ABOUT TALKMED

GRI 102-2 | 102-3 | 102-4 | 102-5 | 102-6 | 102-7 | 102-8

HONG KONG

Hong Kong Integrated Oncology Centre Holdings Limited is the controlling shareholder of Hong Kong Integrated Oncology Centre Limited, which provides a comprehensive range of services with the concept of “Total Cancer Care” and “Tumor Board Approach” through its day care medical centres. The services include cancer prevention, screening, imaging and diagnosis, multidisciplinary cancer treatment (including in-patient treatment and radiotherapy through its strategic partnership with Hong Kong Adventist Hospital) and after-treatment care in Hong Kong.

VIETNAM

TalkMed Vietnam Pte. Ltd. was established in March 2014 and we collaborated with Thu Cuc International General Hospital to set up a medical centre known as Singapore Cancer Centre Thu Cuc. The centre provides specialist medical oncology services in Hanoi, Vietnam.

SCALE OF ORGANISATION

Net Revenue:

S\$60,746,000



Total Employees⁽¹⁾:

92



Total Operations:

9 clinics



Full-time (Male):

18



Full-time (Female):

74



(1) All our employees are full-time and permanent, except for five (5) employees who are part-time and permanent.

SUSTAINABILITY AT TALKMED

GRI 102-11 | 102-16 | 102-18

TalkMed is committed to integrating sustainability across all our functions. We have put in place relevant policies and procedures to ensure efficient management of sustainability within our Group.

The goal of the Company is to provide services of the highest quality to our customers, which is reflected in our vision and mission.

Vision: *Our vision is to be a premier provider of medical oncology and palliative care healthcare services in the private sector in Singapore and in the region.*

Mission: *Our mission is to deliver quality care and service to our patients. Looking ahead, providing medical oncology and palliative care healthcare services in the region and expanding our services to include the provision of secondary and primary healthcare are also an integral part of our business model.*

While managing our environmental, social and governance risks, TalkMed considers the Precautionary Principle and supports it by taking actions to reduce our environmental impacts.

GOVERNANCE STRUCTURE

Our senior management is responsible for leading our sustainability efforts and initiatives. They communicate and update the Board of Directors about our sustainability progress on an on-going basis to help them formulate relevant strategies.

We pride ourselves in conducting our business in a clean, ethical and transparent manner. We have clear policies on business standards, ethics and anti-corruption and are committed to ensuring full compliance with local as well as international requirements. We do not condone any malpractice, impropriety, non-compliance of statutory law, rules and regulations, or wrongdoing by employees in the course of performing their duties. More information on our corporate governance guidelines and practice is available on pages 16 to 36 of our FY21 Annual Report.



STAKEHOLDER ENGAGEMENT

GRI 102-40 | 102-42 | 102-43 | 102-44

At TalkMed, we understand the importance of engaging our stakeholders and identifying the material issues that are most important to them. We selected our key stakeholder group based on influence, representation, responsibility, dependency and proximity.

We have identified the key material issues through a process of identification, prioritisation and validation via a stakeholder engagement conducted previously.

We firmly believe that stakeholder engagement is a key factor to ensure the success of our business. Therefore, we constantly seek to improve our communication channels with all our stakeholders to seek their inputs as well as address their concerns.

Stakeholder	Concerns Raised	Frequency of Engagement	Mode of Engagement
Shareholders	Economic Performance Customer Health and Safety Employment Anti-corruption	Annually/Ad hoc	Half-yearly financial results Annual general meeting Email
Patient	Customer Health and Safety Customer Privacy Product Service and Labelling	Ad hoc	Informal feedback from patients through our doctors and clinical staff Face to face interaction Public forum
Supplier	Procurement Practices Market Practices Customer Health and Safety	Ad hoc	Feedback via email / phone call
Regulator	Compliance (Product Responsibility) Customer Health and Safety Compliance (Society) Anti-corruption	Ad hoc/Quarterly	Regulatory guidelines Email Phone call
Employee	Employment Training and Education Occupational Health and Safety	Ad hoc/Annually	Email Yearly appraisals Team building sessions
Top Management	Economic Performance Customer Health and Safety Indirect Economic Impacts Anti-corruption	Ad hoc/Quarterly	Board meetings Board Committee meetings

MATERIALITY ASSESSMENT

GRI 102-46 | 102-47 | 103-1

The content and aspect boundaries in this report have been developed in alignment with the GRI Reporting Principles of Materiality, Stakeholder Inclusiveness, Sustainability Context and Completeness. Our key stakeholders were engaged through carefully formulated surveys to understand their areas of concern.

TalkMed conducted a peer benchmarking exercise in the financial year ended 31 December 2019 ("FY19"). We compared the material topics and disclosures against our top local and national peers to assess gaps and identify areas of improvement. After analysing the findings from the exercise, we have refreshed our material aspects and selected "Anti-corruption" as an additional material aspect to be included in our Sustainability Report from FY19 onwards.

We are committed to updating our materiality assessment regularly.

MATERIAL ASPECTS AND INDICATORS IDENTIFIED

Categories	Material Aspects	List of Indicators	Aspect Boundary
Economic	Economic Performance	GRI 201-1: Direct economic value generated and distributed	Within organisation
Governance	Anti-corruption	GRI 205-3: Confirmed incidents of corruption and actions taken	Within organisation
Product Responsibility	Customer Health and Safety	GRI 416-2: Incidents of non-compliance concerning the health and safety impacts of products and services	Within organisation and patients
Labour Practices and Decent Work	Employment	GRI 401-1: New employee hires and employee turnover	Within organisation
	Training and Education	GRI 404-1: Average hours of training per year per employee	Within organisation

GOVERNANCE

ANTI-CORRUPTION

GRI 103-1 | 103-2 | 103-3 | 205-3

Why is this a material issue?

TalkMed adheres to the highest standards of business integrity, ethics and transparency. Corruption in any form undermines the capability of healthcare organisations to contribute to better health and to serve their customers well. Hence, it is important for us to keep our corruption risk low through good corporate governance, business ethics and strong internal controls in our business processes.

As a medical services provider, we take this issue very seriously and are committed to complying with all applicable standards, rules and regulations necessary to prevent corruption and unethical behaviour.

Our approach to managing

At TalkMed, we have zero tolerance for all forms of corruption, bribery, fraud and unethical behavior. This is reflected in our Code of Conduct, which outlines the guidelines for maintaining transparency and accountability.

We have also established a whistle-blowing policy which will stipulate the mechanism by which concerns about plausible improprieties in matters of financial reporting may be raised. A dedicated secured email address allows whistle-blowers direct access to the Audit and Risk Committee.

The whistle-blowing policy and its procedures have also been made available to all employees.

The Company's whistle-blowing policy allows employees to raise concerns and offers reassurance that they will be protected from reprisals or victimisation for whistle-blowing in good faith.

FY21 Performance

There were no reported cases of corruption during the reporting period.

FY22⁽²⁾ Target

We aim to maintain zero cases of all forms of corruption in our future business operations as well.

(2) Financial year ending 31 December 2022 ("FY22")

PRODUCT RESPONSIBILITY

CUSTOMER HEALTH AND SAFETY

GRI 103-1 | 103-2 | 103-3 | 416-2

Why is this a material issue?

The safety and well-being of our customers form the core of our organisation's value. We are committed to providing excellent service to our patients at all times and have taken several measures to ensure the same.

We have integrated standards and procedures across all our operations and installed continuous monitoring systems to safeguard the health and safety of our valued customers.

Our approach to managing

As customer safety is a crucial aspect of our business, we ensure strict adherence to government regulations such as Private Hospitals and Medical Clinics Act, Medicines Act, Health Products Act and Singapore Medical Council Ethical Code and Ethical Guidelines.

We have in place a set of clinical standard operating procedures ("**SOPs**") to maintain competency among staff and compliance with the applicable regulations and laws.

As a provider of medical services, we believe the professional capability of our nurses is a direct reflection of the quality of our services. We have, therefore, put in place a system of competency checklists to assess and evaluate their proficiency. In addition to this, we also have an apheresis competency checklist, as our operations require handling of blood products. The above SOPs and checklists are reviewed every year for relevance and completeness.

FY21 Performance

There were no incidents of non-compliance concerning the health and safety impacts of products and services.

FY22 Target

TalkMed aims to continue its performance by maintaining a strong framework to ensure compliance with relevant guidelines and regulations.

PEOPLE

EMPLOYMENT

GRI 103-1 | 103-2 | 103-3 | 401-1

Why is this a material issue?

Our employees are the foundation of our business and the secret to our long-lasting success. They are integral to our ability to provide exceptional medical services to our customers and consistently improve our performance. As they are our most valuable assets, we are committed to providing a challenging work environment for our workforce of talented doctors and specialists.

Our approach to managing

We are aware that our ability to attract, develop and retain highly motivated employees is critical to our business.

Our human resource team follows fair and supportive policies which are in line with our objectives. We have an equitable system of recognition and awards that allows doctors the opportunity to participate in revenue-sharing schemes. Our staff is awarded attractive year-end bonus that commensurates with their performances. In addition to the above, we provide annual subsidised holidays to promote staff bonding. We recognise and acknowledge the contribution of our long-serving staff by rewarding them with long service awards.

We aim to have the very best talent and also work towards ensuring that each role is filled by a candidate who is qualified and of the right fit. Therefore, we have delegated this crucial task of recruiting new doctors to our Chief Executive Officer and Chief Operating Officer, while the hiring of new clinical staff is entrusted to nurse management and human resource department. This helps us to identify candidates with high potential who can contribute meaningfully to the Group.

FY21 Performance

Total new hire rate: 7.6%

Total turnover rate: 7.6%

FY22 Target

To ensure greater retention of talent pool.

PEOPLE

EMPLOYEE INFORMATION

Employee information by age group and nationality		Singapore	Other nationality	Total		
Below 30		7	0	7		
Between 30 and 50		40	22	62		
Above 50		19	4	23		
Total employees		66	26	92		
New hires by age group		Male	Female	Rate of hire (male)	Rate of hire (female)	Total rate of hire
Below 30		1	1	100.0%	16.7%	28.6%
Between 30 and 50		0	4	0.0%	66.6%	57.1%
Above 50		0	1	0.0%	16.7%	14.3%
Total employees		1	6			
New hires by nationality		Male	Female	Rate of hire (male)	Rate of hire (female)	Total rate of hire
Singapore		1	4	100.0%	66.7%	71.4%
Other		0	2	0.0%	33.3%	28.6%
Total employees		1	6			
New hires by gender		Number	Percentage			
Male		1	14.3%			
Female		6	85.7%			
Total employees		7				
Employee turnover by age group		Male	Female	Rate of turnover (male)	Rate of turnover (female)	Total rate of turnover
Below 30		0	2	–	28.6%	28.6%
Between 30 and 50		0	3	–	42.8%	42.8%
Above 50		0	2	–	28.6%	28.6%
Total employees		0	7			
Employee turnover by nationality		Male	Female	Rate of turnover (male)	Rate of turnover (female)	Total rate of turnover
Singapore		0	6	–	85.7%	85.7%
Other		0	1	–	14.3%	14.3%
Total employees		0	7			
Employee turnover by gender		Number	Percentage			
Male		0	0.0%			
Female		7	100.0%			
Total employees		7				

PEOPLE

TRAINING AND EDUCATION

GRI 103-1 | 103-2 | 103-3 | 404-1

Why is this issue material?

TalkMed places a strong emphasis on developing talent through training and education programmes. It is necessary for our doctors and specialists to be updated with the latest development in their field to perform to the best of their abilities. Therefore, we provide opportunities for holistic improvement in their competency level and help them reach their full potential.


Our approach to managing

To enable employees to refine their skills, we organise regular training and development programmes to cater to their area of specialisation. We offer our nurses fully-sponsored diploma courses to help them upgrade their qualifications. We have fostered a culture of learning in our organisation and we encourage regular feedback to identify new areas of improvement.

FY21 Performance


Average training hours per employee: 9.0

Average training hours by gender



■ Male ■ Female


Average training hours by employee category



■ Management Staff ■ Clinical Staff ■ Specialist Medical Practitioners

FY22 Target

To maintain average training hours per employee at 9.0 hours.



COMMUNITY

RELAY FOR LIFE 2021

Amidst the COVID-19 pandemic, the 5th edition of the Singapore Cancer Society-TalkMed Relay for Life ("RFL") 2021 had successfully taken place between 20 and 28 March 2021 to raise funds for the cause. TalkMed was the Title Sponsor for RFL and the Group hopes that RFL will raise more awareness about cancer, and more importantly, drive the message that no cancer patient should walk this road alone.

Despite the safe distancing limitations in place at that time, the community-based fund-raising event had attracted over 4,000 participants who showed their never-ending support in the spirit that **Celebrates** the lives of cancer survivors, **Remember** those lost to the disease and **Fight Back** against a disease that has taken so much.

Across the nine-day event, participants accomplished the traditional 100km Challenge (be it running, swimming or cycling) with a team or individually. With the introduction of a new open category called 'My Fight Back Challenge' this year, participants were also able to come up with their own unique ways of staying healthy, both physically and mentally, and execute the activities with their families and friends.

With everyone's efforts and contributions, the event raised approximately S\$1.32 million which would go towards funding the programmes and services run by Singapore Cancer Society to Minimise Cancer and Maximise Lives of the cancer community.



GRI CONTENT INDEX

GRI Standard	Disclosure		Chapter, Page Reference, Performance and/or Explanation for Omissions
GRI 102: General Disclosures 2016	ORGANISATIONAL PROFILE		
	102-1	Name of the organisation	2
	102-2	Activities, brands, products, and services	4 to 6
	102-3	Location of headquarters	4
	102-4	Location of operations	4 to 6
	102-5	Ownership and legal form	4 to 6
	102-6	Markets served	4 to 6
	102-7	Scale of the organisation	6
	102-8	Information on employees and other workers	6
	102-9	Supply chain	Our supply chain involves drugs and consumables that are ordered either through direct pharmaceutical companies or through third party logistic partners.
	102-10	Significant changes to organisation and its supply chain	None
	102-11	Precautionary principle or approach	7
	102-12	External initiatives	<ul style="list-style-type: none"> • Singapore Code of Corporate Governance (2018) • Singapore Financial Reporting Standards (International)
	102-13	Membership of associations	None
	STRATEGY		
	102-14	Statement from senior decision-maker	3
	ETHICS AND INTEGRITY		
	102-16	Values, principles, standards, and norms of behaviour	7
	GOVERNANCE		
	102-18	Governance structure	7
	STAKEHOLDER ENGAGEMENT		
	102-40	List of stakeholder groups	8
	102-41	Collective bargaining agreements	None of our employees are covered under collective bargaining agreements.
	102-42	Identifying and selecting stakeholders	8
102-43	Approach to stakeholder engagement	8	
102-44	Key topics and concerns raised	8	

GRI CONTENT INDEX

GRI Standard	Disclosure		Chapter, Page Reference, Performance and/or Explanation for Omissions
GRI 102: General Disclosures 2016	REPORTING PRACTICE		
	102-45	Entities included in the consolidated financial statements	<ol style="list-style-type: none"> 1. Singapore Cancer Centre Pte. Ltd. 2. TalkMed Vietnam Pte. Ltd. 3. TalkMed Greater China Pte. Ltd. 4. TalkMed China Pte. Ltd. 5. TalkMed Chongqing Pte. Ltd. 6. Stem Med Pte. Ltd.⁽⁶⁾ 7. CellVec Pte. Ltd. 8. Stem Med Indonesia Pte. Ltd.⁽⁶⁾ 9. DrSG Cellular Wellness Pte. Ltd.⁽⁶⁾ 10. Sino-Singapore Hospital Management (Chongqing) Co., Ltd. 11. Sino-Singapore Cancer Centre 12. Chongqing Medtech Health Management Co., Ltd. 13. TalkMed Hospital Management (Beijing) Co., Ltd. 14. Beijing Yachuang Siwei Investment Management Co., Ltd. 15. Beijing Deyi Shanshui Clinic Co., Ltd. 16. Hong Kong Integrated Oncology Centre Holdings Limited 17. Hong Kong Integrated Oncology Centre Limited 18. Hong Kong Integrated Oncology Centre (Kowloon) Limited 19. Cancer Care Consultants Limited <p>Only Singapore Cancer Centre Pte. Ltd. is covered under the scope of the report.</p> <p>⁽⁶⁾ During the year ended 31 December 2021, the Group disposed of its entire equity interest in these entities. Pursuant to the disposal, these entities ceased to be subsidiaries of TalkMed. The financial results of these entities have been consolidated up to the disposal date.</p>
	102-46	Defining report content and topic Boundaries	2 and 9
	102-47	List of material topics	9
	102-48	Restatements of information	We do not have any restatements of information.
	102-49	Changes in reporting	There are no changes in reporting.
102-50	Reporting period	2	

GRI CONTENT INDEX

GRI Standard	Disclosure		Chapter, Page Reference, Performance and/or Explanation for Omissions
REPORTING PRACTICE			
GRI 102: General Disclosures 2016	102-51	Date of the most recent report	May 2021
	102-52	Reporting cycle	2
	102-53	Contact point of questions regarding the report	2
	102-54	Claims of reporting in accordance with GRI Standards	2
	102-55	GRI Content Index	16 to 19
	102-56	External assurance	We have not sought external assurance for this reporting period.
Material Topics			
ECONOMIC			
GRI 103: Management Approach 2016	103-1	Explanation of the material topic and its Boundary	Please refer to pages 5 to 6 of our FY21 Annual Report
	103-2	The management approach and its components	
	103-3	Evaluation of the management approach	
GRI 201: Economic Performance 2016	201-1	Direct economic value generated and distributed	Please refer to pages 47 to 116 of our FY21 Annual Report
GRI 103: Management Approach 2016	103-1	Explanation of the material topic and its Boundary	9 and 10
	103-2	The management approach and its components	10
	103-3	Evaluation of the management approach	10
GRI 205: Anti-corruption 2016	205-3	Confirmed incidents of corruption and actions taken	10
SOCIAL			
GRI 103: Management Approach 2016	103-1	Explanation of the material topic and its Boundary	9 and 12
	103-2	The management approach and its components	12
	103-3	Evaluation of the management approach	12
GRI 401: Employment 2016	401-1	New employee hires and employee turnover	12 to 13

GRI CONTENT INDEX

GRI Standard	Disclosure		Chapter, Page Reference, Performance and/or Explanation for Omissions
SOCIAL			
GRI 103: Management Approach 2016	103-1	Explanation of the material topic and its Boundary	9 and 14
	103-2	The management approach and its components	14
	103-3	Evaluation of the management approach	14
GRI 404: Training and Education 2016	404-1	Average hours of training per year per employee	14
GRI 103: Management Approach 2016	103-1	Explanation of the material topic and its Boundary	9 and 11
	103-2	The management approach and its components	11
	103-3	Evaluation of the management approach	11
GRI 416: Customer Health and Safety 2016	416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	11



101 Thomson Road
#09-02 United Square
Singapore 307591